OnKure Therapeutics, Inc. OKUR Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -42.7%— | -74.4%— | —— | —— | —— | |
| Return on assets | -39.4%+24.7pp | -67.2%+2.7pp | -84.3%— | -73.2%— | -64%— | |
| Liquidity | ||||||
| Current ratio | 13.8×+2.6× | 10.3×-0.5× | 11.4×-12.3× | 11.1×-46.7× | 11.2×-18.6× | |
| Quick ratio | 13.8×+2.6× | 10.3×-0.5× | 11.4×-12.3× | 11.1×-46.7× | 11.2×-18.6× | |
| Cash ratio | 13.4×+2.4× | 10×-0.5× | 11.3×-7.4× | 11×-15.7× | 11×+3.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $13.48+99.7% | $4.16-86.2% | $4.91+101% | $5.79+101% | $6.75+102% | |
| Valuation | ||||||
| Market capitalization | $184.2M+72.6% | $123.71M-65.8% | $117.16M— | $108.91M— | $181.92M— | |
| Enterprise value | -$7.49M-127% | $65.21M-74.1% | $47.51M— | $26.35M— | $86.21M— | |
| Price / book | 1×-0.4× | 2.2×-1.3× | 1.8×— | 1.4×— | 2×— | |
| Free cash flow yield | -27.5%+29.8pp | -41.9%-27.8pp | -54.4%— | -56.3%— | -30%— | |
| Earnings yield | -31.8%+24.5pp | -48.1%-33.5pp | -54.2%— | -55.4%— | -32.5%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do OnKure Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from OnKure Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.